2-Chloro-4-amino-6,7-dimethoxyquinazoline (CAS 23680-84-4, C10H10ClN3O2, relative molecular mass 239.66 g/mol) is not the final alpha-1 blocking drug substance but is manufactured under ICH Q7 and EU GMP Part II as a pharma-grade intermediate because it enters the registered synthetic route of prazosin hydrochloride, doxazosin mesylate, terazosin hydrochloride, and alfuzosin hydrochloride. In prazosin hydrochloride production, the dried material is suspended in anhydrous n-butanol and 1-(2-furoyl)piperazine is charged at 1.05–1.20 molar equivalents relative to the chloroquinazoline, with triethylamine at 1.00–1.10 molar equivalents as hydrogen chloride scavenger. Water is excluded because the C2 chloride hydrolyses to 4-amino-6,7-dimethoxyquinazolin-2(1H)-one in the presence of moisture at reflux; this quinazolinone is not removed by routine acid-base extraction and can depress prazosin base yield. The batch is held at 117–118°C under nitrogen for 18–36 h with HPLC in-process control using a C18 column, pH 6.8 phosphate buffer, and acetonitrile gradient. When conversion is below 98.0 area%, a side-chain re-charge of 0.05–0.15 molar equivalents is made; total side-chain input above 1.30 molar equivalents increases the bis-quinazoline impurity and intensifies resinous colour bodies. After ethyl acetate extraction, sodium chloride solution washing at 55–65°C, activated carbon treatment, and ethanolic hydrogen chloride salt formation, prazosin hydrochloride is obtained. The oral tablets and capsules containing 1 mg, 2 mg, or 5 mg prazosin hydrochloride are produced from granules; compendial testing under the USP Prazosin Hydrochloride monograph and ICH Q3A applies. Under ICH M7, if no compound-specific toxicology data exist, the 1.5 µg/day threshold of toxicological concern applied at the 20 mg/day maximum adult dose yields a residual CADMQ limit of 75 ppm in prazosin hydrochloride. In-house release methods often control the compound at ≤0.005 area% after relative response factor validation to stay within this concentration after excipient dilution and granule drying.

What Limits Residual 2-Chloro-4-Amino-6,7-Dimethoxyquinazoline in Doxazosin Mesylate Tablets?

Residual CADMQ in doxazosin mesylate is controlled as a process impurity because the C2 displacement with 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine is slower than the corresponding furoyl-piperazine reaction. Process development batches conducted in n-butanol at 117–118°C often require 20–36 h to reduce residual chloroquinazoline to <0.10 area% before isolation. The side-chain molar ratio is maintained at 1.10–1.30 relative to CADMQ, and triethylamine at 1.20–1.40 equivalents protects piperazine nucleophilicity by scavenging the liberated HCl; below 1.20 equivalents of triethylamine, the coupling rate falls sharply because the piperazine is partially protonated and the C2 chloride becomes subject to competitive hydrolysis. The isolated doxazosin base is crystallized from ethyl acetate–methanol and filtered at 40–50°C to remove poorly soluble chloroquinazoline-enriched solids; final API after recrystallisation should not exceed 0.005 area% for residual CADMQ. At the 16 mg/day maximum adult dose, the 1.5 µg/day TTC ceiling gives 93.75 ppm for a hypothetical ICH M7 Class 3 classification; the ICH Q3A qualification threshold of 0.15% would allow 1500 ppm and therefore does not drive the control. Tablets of 1 mg, 2 mg, 4 mg, and 8 mg doxazosin mesylate are tested for dissolution under the USP Doxazosin Tablets monograph and for content uniformity under USP General Chapter <905>; the analytical method for residual CADMQ uses a 250 mm × 4.6 mm, 5 µm C18 column and UV detection at 254 nm, with a quantitation limit of ≤0.005% relative to the target API concentration. Extended-release matrix tablets based on hypromellose or polyethylene oxide require dissolution in pH 6.8 phosphate buffer, and residual CADMQ is monitored because the impurity can be released from the hydrated matrix at a rate independent of the API if phase-separated during granule compression.

Terazosin hydrochloride manufacture uses 1-(tetrahydro-2-furoyl)piperazine in place of the furoyl side chain, and because the tetrahydrofuroyl ring is less oxidatively sensitive than the furan ring, the n-butanol coupling at 110–118°C can be extended to 24 h without excessive discoloration. The side-chain molar ratio is held at 1.05–1.15 relative to CADMQ; ratios above 1.15 produce a bis-quinazoline impurity that co-migrates with terazosin base on silica gel TLC and is difficult to remove by ethanol–water crystallisation. Potassium carbonate at 1.10–1.20 molar equivalents is used as the base in place of triethylamine, and the resulting potassium chloride is removed by filtration after reaction. The free base is extracted into dichloromethane, washed with water at pH 7–8, and converted to terazosin hydrochloride dihydrate. The final API is either dry granulated or air-jet milled to pass a 250 µm sieve for capsule filling at 1 mg, 2 mg, 5 mg, and 10 mg strengths. Incoming CADMQ for terazosin production is controlled at ≥98.5 area% by HPLC, with the 2-quinazolinone hydrolysis product limited to ≤0.20% and 2,4-diamino-6,7-dimethoxyquinazoline limited to ≤0.10%. At the 20 mg/day maximum dose of terazosin, the ICH M7 default TTC concentration is 75 ppm; capsule stability studies under ICH Q1A(R2) monitor CADMQ at 40°C/75% RH for 6 months to detect any degradation-related reformation or retarded degradation of the impurity in the finished matrix.

When Alfuzosin Hydrochloride Requires the 2-Chloroquinazoline to Undergo N-Methylpropylamination

Alfuzosin hydrochloride differs from the piperazine-containing analogues because the C2 substituent is (3-(tetrahydrofuran-2-carboxamido)propyl)(methyl)amino. The chloroquinazoline is reacted with N-methyl-1,3-diaminopropane in anhydrous dimethylformamide at 85–110°C, using 2.0–3.0 molar equivalents of the diamine relative to CADMQ and potassium carbonate at 1.20–1.40 equivalents to suppress dimeric 2,2′-bridged quinazoline formation. Moisture in DMF must remain below 0.15% by Karl Fischer; above this level at 100°C the C2 chloride hydrolyses to 4-amino-6,7-dimethoxyquinazolin-2(1H)-one, and the resulting impurity is poorly resolved from the aminopropylamino intermediate on normal-phase silica. After aqueous work-up at 55–65°C, the substituted diamine intermediate is acylated with tetrahydrofuran-2-carbonyl chloride in dichloromethane at 0–5°C; unreacted acid chloride is destroyed with dilute sodium bicarbonate. The alfuzosin base is isolated as the hydrochloride salt and formulated into a 10 mg prolonged-release tablet by hypromellose matrix granulation. Under ICH M7, the 10 mg/day maximum dose gives a residual CADMQ limit of 150 ppm at the 1.5 µg/day TTC, but the release specification is usually tightened to ≤0.010 area% because the once-daily extended-release matrix retains the dose in the gastrointestinal tract for up to 24 h. Dissolution of alfuzosin hydrochloride extended-release tablets is carried out in pH 6.8 phosphate buffer using USP Apparatus 2 at 100 rpm; the system suitability solution containing CADMQ at 0.1% relative concentration is used to confirm resolution from the quinazolinone hydrolysis product before release testing.

Beyond intermediate use, 2-chloro-4-amino-6,7-dimethoxyquinazoline is issued as a qualified reference standard for the HPLC determination of residual starting material in prazosin hydrochloride, doxazosin mesylate, terazosin hydrochloride, and alfuzosin hydrochloride release testing. The reference material is characterised by mass balance, qNMR, differential scanning calorimetry, and headspace GC residual solvent analysis, with an assigned purity ≥99.5%. Stock solutions at 0.5 mg/mL to 1.0 mg/mL in acetonitrile are stored in amber glass at 2–8°C and are validated for use within 72 h; after this period, peak area drift exceeds 2.0% in some validated methods unless fresh calibrants are prepared. A typical HPLC system uses a 250 mm × 4.6 mm, 5 µm C18 column operated at 25°C, a mobile phase of 0.02 M potassium phosphate buffer at pH 6.8 and acetonitrile in gradient elution at 1.0 mL/min, and UV detection at 254 nm. System suitability requires a resolution >2.0 between CADMQ and 2,4-diamino-6,7-dimethoxyquinazoline, theoretical plates >5000 for the CADMQ peak, and a tailing factor between 0.8 and 2.0. The standard is used in forced degradation studies under ICH Q1A(R2); in 0.1 M sodium hydroxide at 80°C the compound converts to the 2-hydroxy analogue, so analytical solutions for tablet and capsule extraction are buffered at pH 6.8 to avoid on-bench degradation. Finished tablets, capsules, and granules are extracted with methanol–0.1% acetic acid 80:20 v/v, and recovery is assessed across 0.005%, 0.010%, and 0.015% spiked levels with acceptance 80–120%. If an injectable dosage form is developed, the residual CADMQ limit is still calculated by total daily dose against the ICH M7 TTC, but the finished injectable must additionally comply with USP <788> for sub-visible particulates and USP <85> for bacterial endotoxins; the CADMQ reference standard itself is not a dosage-form matrix and does not define those limits.

Medicinal chemistry laboratories also use the compound as a C2 electrophilic scaffold for parallel synthesis of substituted 4-amino-6,7-dimethoxyquinazolines with selectivity for α1-adrenergic subtypes. In these small-scale applications, the chloroquinazoline is dispensed as a 0.5 M stock in anhydrous DMF or NMP, and primary or secondary amines are added at 1.2–2.0 equivalents with diisopropylethylamine at 1.5 equivalents. The reactions are heated at 80–110°C for 6–18 h in sealed vials under nitrogen; the C4 amino group is generally not protected because it remains insufficiently nucleophilic under these conditions. Preparative C18 HPLC with mass-directed fractionation isolates the 2-substituted products, and CADMQ input purity is controlled at ≥98% by LC-MS before library production. These research products feed into receptor-binding assays for α1A, α1B, and α1D; the chloroquinazoline itself is not administered as a drug substance in these studies. Data generated from such programmes are later used in ICH M7 hazard assessments and in designing plant-scale process routes for candidate APIs.